Table 4.

Multivariate analysis for the entire cohort and grade III/IV subgroups.

	Adjusted HR	95% CI	p-value
WHOLE COHORT
Progression-free survival (PFS)
Grade IV vs. grade III	0.573	0.278–1.181	0.131
Cerebrum vs. other	1.623	0.719–3.665	0.244
STR/biopsy vs. GTR	0.262	0.089–0.775	0.015
CT after RT/CRT (yes vs. no)	3.391	1.526–7.218	0.002
Temozolomide (yes vs. no)	1.513	0.746–3.068	0.251
Overall survival (OS)
Grade IV vs. grade III	0.540	0.241–1.210	0.135
Cerebrum vs. other	1.621	0.710–3.701	0.252
STR/biopsy vs. GTR	0.202	0.060–0.683	0.010
Seizure vs. no seizure	1.431	0.528–3.880	0.482
CT after RT/CRT (yes vs. no)	4.187	1.856–9.442	0.001
Grade III
Progression-free survival (PFS)
Cerebrum vs. other	1.97	0.586–6.645	0.273
STR/biopsy vs. GTR	0.57	0.128–2.571	0.467
Overall survival (OS)
Cerebrum vs. other	1.81	0.519–6.286	0.353
STR/biopsy vs. GTR	0.16	0.034–0.743	0.019
Grade IV
Progression-free survival (PFS)
Seizure vs. no seizure	3.26	0.969–10.991	0.056
Cranial nerve deficit (yes vs. no)	0.38	0.110–1.316	0.127
Cerebrum vs. other	1.52	0.625–3.716	0.354
STR/biopsy vs. GTR	0.64	0.143–2.887	0.564
Temozolomide (yes vs. no)	2.49	0.896–6.898	0.080
Overall survival (OS)
Seizure vs. no seizure	4.20	1.181–14.969	0.027
Cranial nerve deficit (yes vs. no)	0.57	0.133–2.009	0.383
Cerebrum vs. other	1.75	0.613–4.969	0.297
STR/biopsy vs. GTR	0.99	0.216–4.520	0.988
Temozolomide (yes vs. no)	1.24	0.418–3.705	0.694

STR, sub-total resection; GTR, gross total resection; CT, chemotherapy; RT, radiation therapy; RT, chemoradiation.

Bold indicates significant value (p ≤ 0.05).